The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and Medicare population.

Initiating average-risk CRC screening at age 45 instead of age 50 increases the estimated clinical benefit by reducing disease burden while remaining cost-effective. Among stool-based screening modalities, mt-sDNA provides the most clinical benefit in a Commercial and Medicare population.